{"id":"NCT00949533","sponsor":"Hoffmann-La Roche","briefTitle":"A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza","officialTitle":"A Phase IIIb, Open-label, Comparative, Randomized Study on Resistance of Influenza A/H1N1 2009 Virus to Treatment With Oseltamivir at Standard Dose Versus Double Dose","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2009-07-30","resultsPosted":"2016-08-08","lastUpdate":"2016-08-08"},"enrollment":37,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Oseltamivir","otherNames":["Tamiflu"]}],"arms":[{"label":"Standard Dose","type":"EXPERIMENTAL"},{"label":"Double Dose","type":"ACTIVE_COMPARATOR"}],"summary":"This open-label randomized 2 arm study will determine the emergence of viral resistance in participants with seasonal influenza A infection treated with oseltamivir. Eligible participants less than or equal to (\\</=) 5 years of age will be randomized to receive oseltamivir at either standard dose (30-75 milligrams \\[mg\\] orally twice daily \\[bid\\]) or double dose (60-150 mg orally bid) for 5 days. Target sample size is greater than (\\>) 100.","primaryOutcome":{"measure":"Percentage of Participants Excreting Resistant Virus","timeFrame":"Day 5","effectByArm":[{"arm":"Standard Dose","deltaMin":26.3,"sd":null},{"arm":"Double Dose","deltaMin":35.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.825"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":3,"countries":["Brazil"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Vomiting","Abdominal pain","Diarrhoea","Nausea","Abdominal cramps"]}}